Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia

Schizophrenia Bulletin

Volumn 34, Issue 3, 2008, Pages 494-506

  Hill, S Kristian ^a   Reilly, James L ^a   Harris, Margret S H ^a   Khine, Tin ^a   Sweeney, John A ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Cognition; Neuropsychology; Oculomotor; Schizophrenia

Indexed keywords

BENZATROPINE; BIOLOGICAL MARKER; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; EYE MOVEMENT CONTROL; FEMALE; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; MALE; MEMORY; MONOTHERAPY; MOTOR PERFORMANCE; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SACCADIC EYE MOVEMENT; SCHIZOPHRENIA; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TEST RETEST RELIABILITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ORIENTATION; WORKING MEMORY; COGNITION; HOSPITALIZATION;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; RISPERIDONE; SACCADES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 46849095050     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm112     Document Type: Article

References (63)

1. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549-559.
2. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
3. Hill SK, Keshavan MS, Sweeney JA. Neuropsychological profile comparison of unmedicated first-episode schizophrenia, psychotic depression, unipolar depression and healthy individuals with no mental illness. Am J Psychiatry. 2004;161:996-1003.
4. Green MF, Nuechterlein KH. Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull. 1999;25:309-318.
5. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31:5-19.
6. Buchanan RW, Koeppl P, Breier A. Stability of neurological signs with clozapine treatment. Biol Psychiatry. 1994;36:198-200.
7. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenia. Schizophr Bull. 1990;16:477-499.
8. Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic- naïve patients with schizophrenia. Schizophr Res. 2004;68:49-63.
9. Rollnik JD, Borsutzky M, Huber TJ, et al. Short-term cognitive improvement in schizophrenics treated with typical and atypical neuroleptics. Neuropsychobiology. 2002;45:74-80.
10. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018-1028.
11. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry. 2002;51:972-978.
12. Harvey PD, Moriarty PJ, Serper MR, Schnur E, Lieber D. Practice-related improvement in information processing with novel antipsychotic treatment. Schizophr Res. 2000;46:139-148.
13. Keefe RSE, Perkins S, Silva SM, Lieberman JA. The effect of atypical antipsychotic drugs on neurocognitive function in schizophrenia. Schizophr Bull. 1999;25:201-222.
14. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry. 2000;57:249-258.
15. Arnsten AFT. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci. 1998;2:436-447.
16. Birnbaum SG, Podell DM, Arnsten AFT. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug FG7142, in rats. Pharmacol Biochem Behav. 2000;67:397-403.
17. Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC, et al. Cognitive inflexibility after prefrontal serotonin depletion. Science. 2004;304:878-880.
18. Murphy ER, Dalley JW, Robbins TW. Local glutamate receptor antagonism in the rat prefrontal cortex disrupts response inhibition in a visuospatial attentional task. Psychopharmacology. 2005;179:99-107.
19. Ragozzino ME. The effects of dopamine D-sub-1 receptor blockade in the prelimbic-infralimbic areas of behavioral flexibility. Learn Mem. 2002;9:18-28.
20. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficits caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 1979;205:929-932.
21. Arnsten AFT, Cai JX, Steere JC, Goldman-Rakic PS. Dopamine D2-receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. J Neurosci. 1995;15:3429-3439.
22. Chapman LJ, Chapman JP. Disordered Thought in Schizophrenia. New York, NY: Appleton, Century Crofts; 1973.
23. Keefe RSE. The contribution of neuropsychology to psychiatry. Am J Psychiatry. 1995;52:6-15.
24. Strauss ME, Summerfelt A. The need to integrate neuropsychological and experimental schizophrenia research: response. Schizophr Bull. 1994;20:13-21.
25. Barrett SL, Bell R, Watson D, King DJ. Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. J Psychopharmacol. 2004;18:156-172.
26. Burke JG, Reveley MA. Improved antisaccade performance with risperidone in schizophrenia. J Neurol Neurosurg Psychiatry. 2002;72:449-454.
27. Schuepbach D, Hill SK, Sanders RD, Keshavan MS, Sweeney JA. Early, treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: a two-year follow-up. Schizophr Bull. 2004;30:837-848.
28. Harris MSH, Reilly JL, Keshavan MS, Sweeney JA. Longitudinal studies of antisaccades in anti-psychotic-naïve first-episode schizophrenia. Psychol Med. 2006;36:485-494.
29. Reilly JL, Harris MS, Keshavan MS, Sweeney JA. Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia. Biol Psychiatry. 2005;57:145-154.
30. Reilly JL, Harris MSH, Keshavan MS, Sweeney JA. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry. 2006;63:1189-1197.
31. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press; 1997.
32. Ammons CH, Ammons RB. The Quick Test (QT): provisional manual. Psychol Rep. 1962;11:111-161.
33. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991;48:739-745.
34. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1998;75:800-802.
35. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New Jersey, NJ: Lawrence Erlbaum; 1988.
36. Fagerlund B, Mackeprang T, Gade A, Hemmingsen R, Glenthoj BY. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naïve schizophrenic patients. CNS Spectr. 2004;9:364-374.
37. Harvey PD, Green MF, McGurk SR, Meltzer M. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double blind, randomized study. Psychopharmacology. 2003;169:404-411.
38. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trail. Am J Psychiatry. 2005;162:1888-1895.
39. Flechtner KM, Steinacher B, Sauer R, Mackert A. Smooth pursuit eye movements of patients with schizophrenia and affective disorder during clinical treatment. Eur Arch Psychiatry Clin Neurosci. 2002;252:49-53.
40. Gooding DC, Mohapatra L, Shea HB. Temporal stability of saccadic task performance in schizophrenia and bipolar patients. Psychol Med. 2004;34:921-932.
41. Sweeney JA, Bauer KS, Keshavan MS, Haas GL, Schooler NR, Kroboth PD. Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naïve schizophrenic patients. Neuropsychopharmacology. 1997;16:217-228.
42. Johnson-Selfridge M, Zalewski C. Moderator variables of executive functioning in schizophrenia: meta-analytic findings. Schizophr Bull. 2001;27:305-316.
43. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8:1-16.
44. Braff DL, Light GA. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology. 2004;174:75-85.
45. Broerse A, Crawford TJ, Den Boer JA. Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study. J Neuropsychiatry Clin Neurosci. 2002;14:454-460.
46. Hutton SB, Joyce EM, Barnes TRE, Kennard C. Saccadic distractibility in first-episode schizophrenia. Neuropsychologia. 2002;40:1729-1736.
47. Muller N, Riedel M, Eggert T, Straube A. Internally and externally guided voluntary saccades in unmedicated and medicated schizophrenic patients. Part II. Saccadic latency, gain, and fixation suppression errors. Eur Arch Psychiatry Clin Neurosci. 1999;249:7-14.
48. Straube A, Riedel M, Eggert T, Muller N. Internally and externally guided voluntary saccades in unmedicated schizophrenic patients. Part I: Saccadic velocity. Eur Arch Psychiatry Clin Neurosci. 1999;249:1-6.
49. Crawford TJ, Haeger B, Kennard C, Reveley MA, Henderson L. Saccadic abnormalities in psychotic patients. II. The role of neuroleptic treatment. Psychol Med. 1995;25:473-483.
50. Hutton SB, Puri BK, Duncan LJ, Robbins TW, Barnes TRE, Joyee EM. Executive function in first-episode schizophrenia. Psychol Med. 1998;28:463-473.
51. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354:472-482.
52. Reilly JL, Harris MSH, Khine TT, Keshavan MS, Sweeney JA. Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biol Psychiatry. 2007;62:818-821.
53. Arnsten AFT, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D-sub-1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology. 1994;116:143-151.
54. Funahashi S, Bruce CJ, Goldman-Rakic PS. Visuospatial coding in primate prefrontal neurons revealed by oculomotor paradigms. J Neurophysiology. 1990;63:814-831.
55. Light GA, Braff DL. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry. 2005;162:1741-1743.
56. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe M, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68:283-297.
57. Barua P, Bilder R, Small A, Sharma T. Standardization and cross-validation study of cogtest an automated neurocognitive batter for use in clinical trials of schizophrenia. Schizophr Bull. 2002;31:318.
58. Sahakian BJ, Owen AM. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med. 1992;85:399-402.
59. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test (CVLT) Manual. New York, NY: The Psychological Corporation; 1983.
60. Wechsler DA. Wechsler Memory Scale Revised (WMS-R). Cleveland, OH: The Psychological Corporation; 1987.
61. Wechsler DA. Wechsler Adult Intelligence Scale Revised (WAIS-R), Manual. Cleveland, Ohio: The Psychological Corporation; 1981.
62. Benton AL, Hamsher K. Multilingual Aphasia Examination Manual (Revised). Iowa City: University of Iowa; 1978.
63. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. (2nd ed.) Tucson, Ariz: Neuropsychology Press; 1993.